equity raise unlikely due to the bridging loan before R&D tax benefit is received
the real concern and why I believe the selling from Gary and others has been so staunch is because of the news from GSK on their FDA approved myelofibrosis drug
https://pharmaphorum.com/news/gsk-gets-wide-fda-approval-myelofibrosis-drug
PXS great but slow, Big Pharma appears to be working more in-house and only making big investments when significant positive data and analysis is produced by small biotechs for high commercial targets
Ann: Nature Cancer Publishes Results of PXS Garvin Collaboration, page-10
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.3¢ |
Change
-0.001(2.94%) |
Mkt cap ! $39.40M | |||
| Open | High | Low | Value | Volume |
| 3.4¢ | 3.4¢ | 3.2¢ | $46.51K | 1.381M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 186766 | 3.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 196199 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |